Extracellular Vesicle Therapy for Diabetic Retinopathy
细胞外囊泡治疗糖尿病视网膜病变
基本信息
- 批准号:10723000
- 负责人:
- 金额:$ 48.01万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-30 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:AcidsAddressAdhesionsAffectAftercareAngiogenic FactorAreaBindingBiological ProductsBlindnessBlood VesselsCell CommunicationCell secretionCellsChoroidal NeovascularizationClinicalComplementControl GroupsDeteriorationDevelopmentDiabetes MellitusDiabetic RetinopathyDiameterDiseaseEarly treatmentEconomic BurdenEngineeringEpigenetic ProcessExtravasationFibrosisFosteringFunctional disorderGenesGlucoseGoalsHomeostasisHypoxiaImmuneInflammationInjectionsIntegrinsLabelLeukocytesLigandsLight CoagulationMacrophageMetabolicMicroRNAsModelingModificationMuller&aposs cellNeurogliaNeuronsOxygenPathologicPathway interactionsPatientsPenetrationPersonsPhysiologicalPlayPopulationProcessProgressive DiseasePublic HealthRGD (sequence)ResearchRetinaRetinal DiseasesRetinal NeovascularizationRisk FactorsRoleSiteSourceSteroidsStreptozocinStressSubgroupSystemTestingTherapeutic AgentsVascular DiseasesVascular PermeabilitiesVisionVisual impairmentage groupangiogenesisbevacizumabbiomaterial compatibilitycell typediabetes managementdiabeticearly screeningefficacy testingexosomeextracellular vesiclesglial activationinnovationlaser photocoagulationmacular edemamolecular targeted therapiesmouse modelnanosizedneovascularizationneuroprotectionneurovascularneurovascular unitnovel strategiesnovel therapeutic interventionnovel therapeuticspreventrecruitretinal angiogenesissocioeconomicsstem cellstargeted deliverytranslational applicationstreatment strategyuptake
项目摘要
PROJECT SUMMARY
Diabetic retinopathy (DR) is a leading cause of severe vision loss, affecting nearly 100 million people globally
and over 4 million in the US. Long-standing microangiopathy-driven diabetic macular edema (DME) and retinal
neovascularization (NV) are the major causes of severe vision loss in advanced stages of DR. Thus, inhibition
of aberrant angiogenic factors using an injection of anti-VEGF, steroid, or laser photocoagulation therapy is the
current mainstay for treating advanced DR, however, often fail to resume vision. Since DR remains asymptomatic
until the disease is significantly advanced, screening of early DR and tight control of modifiable systemic risk
factors is a current strategy to manage the early stages of DR. Therefore, developing treatment directly
addressing early pathologic changes in DR, thus preventing visual impairment is a significant unmet need. More
recent studies indicate that diabetes injures the retinal neurovascular unit (NVU) and its interdependent vascular,
neuronal, glial, and immune cells during the development of DR. The long-term goal of our studies is to develop
a new treatment strategy to realign the disrupted neurovascular microenvironment in DR that protects the retina
and visual function. The overall objectives of this application are to test two treatment strategies in DR that
complement each other: 1) active targeting of DR that allows targeted delivery of therapeutic agents to the areas
of retinal vascular dysfunction in its various stages, and 2) intraocular Müller glia-derived exosome treatment to
modulate microenvironment of NVU. Recently, we have shown that exosomes decorated with ASL (ASL-Exo),
composed of Anchor, Spacer, and Arg-Gly-Asp acid (RGD) Ligand-modification actively targets choroidal
neovascularization (CNV). RGD is one of the major ligands and specifically binds a subgroup of integrins that
play an essential role in retinal inflammation, vascular leakage, angiogenesis, and fibrosis in DR. Further, Müller
glia is a major source of neuroprotective and vascular permeability factors, antioxidative activity and epigenetic
modulators. The central hypothesis of this proposal is that bioactive molecules contained in Müller glia-derived
exosomes promote homeostasis of NVU in DR. The central hypothesis will be tested by pursuing two specific
aims. Aim 1 is to evaluate the targeted distribution of intravitreally delivered ASL-Exo to dysfunctional retinal
vasculature in DR. Aim 2 is to determine whether Müller glia-derived ASL-Exo (Müller-ASL-Exo) suppresses DR
by protecting the retina from microangiopathy, inflammation, glial activation, and NV formation and epigenetic
alternation within the retina. The research proposed in this application will test an innovative and novel strategy
that has a great potential to change the current treatment paradigm from passive targeting-directed monotherapy
to active targeting-directed multimolecular target for the treatment of various stages of DR.
项目摘要
糖尿病视网膜病变(DR)是严重视力丧失的主要原因,影响全球近1亿人
在美国超过400万。长期存在的微血管病驱动的糖尿病性黄斑水肿(DME)和视网膜病变
新生血管(NV)是DR晚期严重视力丧失的主要原因。
使用注射抗VEGF、类固醇或激光光凝治疗的异常血管生成因子是
然而,目前用于治疗晚期DR的主要药物通常不能恢复视力。由于DR仍无症状
直到疾病显著进展,筛查早期DR并严格控制可改变的系统性风险
因素是当前管理DR早期阶段的策略。因此,直接开发治疗方法
解决DR中的早期病理变化,从而预防视力损害是一个显著未满足的需求。更
最近的研究表明糖尿病损害视网膜神经血管单元(NVU)及其相互依赖的血管,
神经元,神经胶质细胞和免疫细胞在DR的发展。我们研究的长期目标是发展
一种新的治疗策略,重新调整DR中被破坏的神经血管微环境,保护视网膜
和视觉功能。本申请的总体目标是测试DR中的两种治疗策略,
相互补充:1)DR的主动靶向,其允许将治疗剂靶向递送至
视网膜血管功能障碍的不同阶段,和2)眼内Müller胶质源性外泌体治疗,
调节NVU微环境。最近,我们已经证明了用ASL修饰的外泌体(ASL-Exo),
由锚、间隔和Arg-Gly-Asp酸(RGD)组成
新生血管形成(CNV)。RGD是主要配体之一,并特异性结合整合素亚组,
在DR的视网膜炎症、血管渗漏、血管生成和纤维化中发挥重要作用。
神经胶质是神经保护和血管通透性因子、抗氧化活性和表观遗传的主要来源。
调制器。这一建议的中心假设是,Müller胶质源性神经胶质细胞中含有的生物活性分子,
外泌体促进DR中NVU的稳态。
目标。目的1是评估玻璃体内递送的ASL-Exo在功能障碍性视网膜病变中的靶向分布。
目的2是确定Müller胶质源性ASL-Exo(Müller-ASL-Exo)是否抑制DR
通过保护视网膜免受微血管病、炎症、神经胶质活化和NV形成和表观遗传
视网膜内的交替。本申请中提出的研究将测试一种创新和新颖的策略
这有很大的潜力改变目前的治疗模式,从被动靶向单一治疗,
涉及用于治疗DR的各个阶段的主动靶向多分子靶向。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sun Young Lee其他文献
Sun Young Lee的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sun Young Lee', 18)}}的其他基金
Exosome based intraocular therapy combined with active targeting of ocular neovascularization
基于外泌体的眼内治疗联合主动靶向眼部新生血管
- 批准号:
10690935 - 财政年份:2022
- 资助金额:
$ 48.01万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 48.01万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 48.01万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 48.01万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 48.01万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 48.01万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 48.01万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 48.01万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 48.01万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 48.01万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 48.01万 - 项目类别:
Research Grant